| 摘要 |
Sublingual tablet formulation containing ketorolac in the form of a pharmaceutically acceptable salt, in particular the tromethamine salt, is disclosed. The formulation is bioequivalent to other conventional oral dosage forms of ketorolac, and has the advantage that the active substance contained in the formulation is much more rapidly absorbed.
|
